Should intravesical Bacillus Calmette–Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?-Reference-Cited by-同舟云学术

Should intravesical Bacillus Calmette–Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?

Published:2018-11-29 Issue:11 Volume:13 Page:e0208267
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yuk Hyeong Dong,Jeong Chang Wook,Kwak Cheol^ORCID,Kim Hyeon Hoe,Ku Ja Hyeon^ORCID

Funder

the National Research Foundation of Korea

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference19 articles.

1. Epidemiology and risk factors of urothelial bladder cancer;M Burger;Eur Urol,2013

2. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016;M Babjuk;Eur Urol,2017

3. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016;PE Clark;J Natl Compr Canc Netw,2016

4. The value of a second transurethral resection in evaluating patients with bladder tumours;M Miladi;Eur Urol,2003

5. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials;RJ Sylvester;J Urol,2002

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing Clinical Efficacy of Different Bacillus Calmette-Guérin Strains in Patients With T1 High Grade Bladder Cancer;Anticancer Research;2024-02-29

2. Comparing Clinical Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with T1 High Grade Bladder Cancer;2023-09-15

3. Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations;PLOS ONE;2022-09-08

4. Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors;Cancer Medicine;2021-09-21

Predictive Values of Preoperative Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Long-Term Survival in High-Risk Non-Muscle-Invasive Bladder Cancer Patients: A Single-Centre Retrospective Study

;Cancer Management and Research;2020-10